Last reviewed · How we verify
NCT05918380
Project 3: ACHIEVE- CHD
NA trial testing PAL2 in Coronary Heart Disease in 500 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | University Hospitals Cleveland Medical Center |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 500 |
| Start date | 15 August 2022 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- PAL2
- CINEMA
Conditions studied
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
Sponsor
University Hospitals Cleveland Medical Center
Who can join
Adults 40 to 75, any sex, with Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Project 2) and coronary heart disease (CHD, Project 3), which drive downstream lifespan inequality. All three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. All three projects will also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 3 of the ACHIEVE GREATER Center.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05918380
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PAL2
Trials testing the same drug.
- NCT05330221 — Project 2: ACHIEVE- HF · NA · recruiting
- NCT05295758 — Project 1: ACHIEVE- HTN · NA · terminated
- NCT05061108 — Linkage, Empowerment, and Access to Prevent Hypertension · NA · active not recruiting
Other recruiting trials for Coronary Heart Disease
Currently open trials in the same condition.
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
- NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
- NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting
Other University Hospitals Cleveland Medical Center trials
Trials by the same sponsor.
- NCT06997198 — Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities · Phase 4 · not yet recruiting
- NCT07379814 — Rectus Abdominis Detrusor Myoplasty for Urinary Retention · not yet recruiting
- NCT07499648 — Baby Steps to Care · NA · not yet recruiting
- NCT07497737 — OMT for Adhesive Capsulitis · Phase 4 · not yet recruiting
- NCT06523166 — Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05918380 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Cleveland Medical Center
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05918380.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing